

Seth Salpeter

Co-founder & CTO

Company: **Curesponse**

Curesponse is an innovative cancer diagnostic company developing the next generation of personalized medicine. The company has established a 3-dimensional platform for modeling cancer dynamics and drug response. The system preserves the cancer tissue microenvironment accurately reflecting the cancer growth found in the body and can be harnessed to create a personalized cancer diagnostic to determine drug response. Patients and clinicians can send samples of their tumor to be tested with a panel of anti-cancer therapies predetermined by genomic screening and physician assessment. The patient will then be informed which drug is the preferred therapy for their tumor, optimizing treatment and increasing their chances of survival. Moreover, the test can be used by pharmaceutical companies to expedite their drug development process as well as for clinical trials as a patient inclusion criteria.